The report shows the results of pre-clinical studies in which ITI-3000 vaccination enhanced specific CD4 T cell responses, increased anti-tumor immune responses, and was the ground to initiate the clinical study in polyomavirus-positive MCC patients (NCT05422781-ITI-3000: Merkel Cell Carcinoma—Immunomic Therapeutics) [189]. The gene discussed is CD4; the disease is Merkel cell skin cancer.